SARS-CoV-2
SARS-CoV-2 is a betacoronavirus and the causative agent of COVID-19, the respiratory disease that emerged as a global pandemic.
SARS-CoV-2 is a betacoronavirus and the causative agent of COVID-19, the respiratory disease that emerged as a global pandemic. As an enveloped, positive-sense RNA virus, it infects host cells by engaging the angiotensin-converting enzyme 2 (ACE2) receptor, a key determinant of viral entry and a major target for neutralizing strategies. The virus encodes a set of structural and non-structural proteins that support attachment, genome replication, transcription, and assembly, making it a central organismal target in antiviral drug discovery, vaccine design, and immunologic assay development.
Biomedically, SARS-CoV-2 is studied both as a pathogen and as a target for therapeutics and vaccines. Recent work has focused on viral entry, replication-transcription machinery, and immune recognition, including the spike receptor-binding domain (RBD), nucleoprotein, non-structural protein 5, and the viral helicase nsp13. These studies also intersect with broader host-response and prevention research involving neutralizing antibody responses, B-cell and T-lymphocyte assays, SARS-CoV-2 vaccination, and booster vaccination against COVID-19 outcomes.
Where the papers sit
35 papers from the last 6 months study SARS-CoV-2 directly · updated from PubMed 16 Nov 2026
Study type 1 clinical trial · 1 observational · 14 human data · 18 preclinical · 1 unclassified
Themes 4 themes
-
COVID-19 Vaccine Immunity
Vaccine design is moving toward broader, more durable protection through tandem or divergent RBDs, intranasal delivery, virus-like particles, and combined mRNA formulations. Antibody and T-cell studies repeatedly assess neutralization breadth, memory, isotype profiles, and protection against variants. Booster strategies are increasingly evaluated in vulnerable people, including those with immune-mediated inflammatory disease. Access in rural sub-Saharan Africa remains a practical constraint alongside the immunological advances.
16 papers · 45.7%
-
Broad-Spectrum Antiviral Discovery
Antiviral discovery is moving from single-virus screening toward broad respiratory-virus coverage and structure-guided SARS-CoV-2 optimization. Cyclophilin inhibitors, Amaryllidaceae alkaloids, ALK inhibitors, and nucleoside analog designs are tested against influenza and coronaviruses. Mpro programs refine pyrimidine, thiadiazole, and 6-methoxypyrimidine scaffolds, while docking and machine learning prioritize candidates. Most evidence remains biochemical, computational, or early preclinical, leaving selectivity and clinical translation open.
12 papers · 34.3%
-
CRISPR-Based Molecular Detection
Rapid CRISPR/Cas12a detection is moving toward one-pot workflows that harmonize amplification and cleavage for sensitive, robust testing. Cas12a-G4 DNAzyme platforms broaden the targets beyond nucleic acids while preserving rapid readouts. Wastewater genomic surveillance extends molecular detection into population-level monitoring of viral diversity and transmission. The main open question is how consistently these platforms perform across complex samples and field settings.
3 papers · 8.6%
-
Others — COVID-19 Translational Biology
COVID-19 translational work here spans antioxidant and immunomodulatory treatment, ACE2-directed intracellular delivery, stroke-thrombus pathology, and qPCR biodistribution measurement. Hypericum perforatum and ACE2-PNA conjugates are explored as antiviral interventions, while cerebral hemoglobin and iron suggest mechanisms for COVID-19-associated stroke. Assay validation supports tracking plasmid DNA distribution rather than a therapeutic endpoint. These studies share SARS-CoV-2 relevance but do not establish a single therapeutic direction.
4 papers · 11.4%
Papers
The 35 papers from the last 6 months that study SARS-CoV-2 directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
COVID-19 Vaccine Immunity (16)
- Evaluation of Physics-Based Pose Prediction and the Role of Receptor Flexibility in a Community Antiviral Blind Challenge. Journal of chemical information and modeling · 26 Oct 2026 PMID 42929583
- Immune checkpoint inhibition enhances memory T-cell responses to CEF(T), SARS-CoV-2 spike proteins and ChAdOx1 nCoV-19. Human vaccines & immunotherapeutics · 6 Oct 2026 PMID 42836482
- Availability and accessibility of SARS-CoV-2 vaccines among rural populations in sub-Saharan Africa: a systematic review and meta-analysis protocol. BMJ open · 24 Sept 2026 PMID 42785944
- Co-administration of intranasal parainfluenza virus vaccines expressing antigenically distinct SARS-CoV-2 S antigens elicits broad and durable immunity in hamsters. Journal of virology · 24 Sept 2026 PMID 42782150
- Exploring the potential of Ayush-64 in mitigation of post-coronavirus disease of 2019 complications of Delta variant of severe acute respiratory syndrome coronavirus 2. Phytomedicine : international journal of phytotherapy and phytopharmacology · 10 Sept 2026 PMID 42721823
- A Dual-Membrane Biomimetic Nanoplatform Enables Triple-Modal Therapy Against SARS-CoV-2 Through Viral Decoy, Inflammation Neutralizing, and Intracellular RNAi. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 7 Sept 2026 PMID 42702867
- Virus-like particle display of the SARS-CoV-2 receptor-binding domain using a modular tag/catcher system enhances immunogenicity of a DNA vaccine in mice. Vaccine · 5 Sept 2026 PMID 42700748
- Platelet-derived serotonin drives age-related lung pathology in SARS-CoV-2 infection. Science immunology · 28 Aug 2026 PMID 42664308
- Engineering antigenic breadth against SARS-CoV-2 by pairing divergent RBDs within a single mRNA immunogen. Proceedings of the National Academy of Sciences of the United States of America · 26 Aug 2026 PMID 42647127
- Functional neutralizing and bactericidal antibody responses induced by dual-target immunization with SARS-CoV-2 RBD and Neisseria meningitidis antigens in mice. Vaccine · 12 Aug 2026 PMID 42585813
- The monoclonal antibody VYD2311 potently neutralizes dominant and emerging SARS-CoV-2 variants. JCI insight · 11 Aug 2026 PMID 42579364
- Comparative Analysis of Nucleocapsid- and Spike-Specific Isotype Humoral Immune Responses Following Natural SARS-CoV-2 Infection and Vaccination with Sinopharm, Sinovac, and AstraZeneca. Viral immunology · 7 Aug 2026 PMID 42565654
- Immunogenicity, reactogenicity, and safety of an mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine, mRNA-1083, in adults aged ≥50 years in Japan. Vaccine · 30 Jul 2026 PMID 42531981
- Broad and durable protection against SARS-CoV-2 and SARS-CoV by an intranasal chimpanzee adenovirus vaccine expressing tandem RBDs and nucleocapsid. PLoS pathogens · 24 Jul 2026 PMID 42497177
- A comparison of alternative vaccination strategies for protecting those vulnerable to illness, hospitalization, or death upon infection with SARS-CoV-2. Journal of theoretical biology · 11 Jul 2026 PMID 42435934
- Association between SARS-CoV-2 booster vaccination and hospitalisation and/or death due to COVID-19 in adults with immune-mediated inflammatory diseases: nested case-control study using linked primary-care, hospitalisation and mortality data from England. RMD open · 3 Jul 2026 PMID 42399080
Broad-Spectrum Antiviral Discovery (12)
- Exposure route, not dose, is the primary driver of infection patterns for a respiratory virus. Science advances · 7 Oct 2026 PMID 42842678
- Genomic surveillance of SARS-CoV-2 in Tunisia during the omicron era: insights from the national influenza & other respiratory viruses laboratory. Virology journal · 17 Sept 2026 PMID 42750054
- Exploring the Pyrimidine Scaffold for the Development of SARS-CoV-2 Mpro Inhibitors. ACS infectious diseases · 11 Sept 2026 PMID 42725964
- Discovery of a new class based on 6-methoxypyrimidine as efficient low weight reversible inhibitors of SARS-CoV-2 main protease (Mpro) with antiviral activity. Bioorganic chemistry · 8 Sept 2026 PMID 42710401
- Network pharmacology, and molecular docking studies for two flavonoid compounds isolated from Dodonaea viscosa towards SARS-CoV-2 infection and loaded in lipid nanoparticles. Artificial cells, nanomedicine, and biotechnology · 7 Sept 2026 PMID 42702742
- SARS‑CoV‑2 Associated Shifts in the Upper Respiratory Tract Mycobiome in Non-hospitalized Cases. Mycopathologia · 18 Aug 2026 PMID 42611121
- Machine learning-based prediction of SARS-CoV-2 bioactivity: integrating IC50 regression and activity classification using multi-task neural networks. BMC bioinformatics · 6 Aug 2026 PMID 42557548
- Optimization of the antiviral spectrum of cyclophilin inhibitors targeting respiratory viruses. Antimicrobial agents and chemotherapy · 17 Jul 2026 PMID 42467054
- Discovery of broad-spectrum antiviral activity in Amaryllidaceae alkaloids. Biochemical and biophysical research communications · 8 Jul 2026 PMID 42419220
- Grammatical evolution-based design of nucleotic analogs for SARS-CoV-2's replication-transcription complex. Physical chemistry chemical physics : PCCP · 1 Jul 2026 PMID 42383721
- Structure-guided optimization of N-(5-((2-oxopropyl) thio)-1,3,4-thiadiazol-2-yl) propionamide frameworks as potent SARS-CoV-2 Mpro inhibitor for treating coronavirus disease. Bioorganic chemistry · 18 Jun 2026 PMID 42314596
- Repurposing ALK inhibitors as influenza and corona virus antivirals targeting lymphocyte tyrosine kinase (LTK). Virus research · 9 Jun 2026 PMID 42263913
CRISPR-Based Molecular Detection (3)
- Wastewater-based genomic surveillance uncovers broader SARS-CoV-2 diversity and spatial transmission dynamics in Georgia, January 2023-July 2024. Microbiology spectrum · 29 Sept 2026 PMID 42808729
- Harmonizing amplification and cleavage kinetics through crRNA scaffold mutation enables robust one-pot CRISPR-Cas12 diagnostics. Proceedings of the National Academy of Sciences of the United States of America · 9 Sept 2026 PMID 42715083
- Universal CRISPR/Cas12a-G4 DNAzyme biosensing platform for rapid detection of nucleic acid and non-nucleic acid targets. The Analyst · 1 Sept 2026 PMID 42677878
Others — COVID-19 Translational Biology (4)
- Triple-Action Antioxidant, Antiviral, and Immunomodulatory Effects of Hypericum perforatum Against SARS-CoV-2 Using Chemical-Based and In Vitro Methods. Plant foods for human nutrition (Dordrecht, Netherlands) · 1 Oct 2026 PMID 42821038
- High levels of cell-free hemoglobin and iron in cerebral thrombi of pre-Omicron COVID-19 stroke patients: novel drivers of SARS-CoV-2-induced prothrombotic state. Acta neuropathologica · 29 Aug 2026 PMID 42667425
- Development and fit-for-purpose validation of a qPCR assay for biodistribution assessment of plasmid DNA following electrode-needle device-assisted intramuscular electroporation. International journal of pharmaceutics · 19 Aug 2026 PMID 42617896
- ACE2-PNA conjugates exploit viral endocytosis for targeted intracellular delivery and exhibit dual antiviral efficacy against SARS-CoV-2. Molecular biomedicine · 3 Aug 2026 PMID 42545604
By study type
Clinical trials (1)
- Immunogenicity, reactogenicity, and safety of an mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine, mRNA-1083, in adults aged ≥50 years in Japan. Vaccine · 30 Jul 2026 PMID 42531981
Observational studies and case reports (1)
- Association between SARS-CoV-2 booster vaccination and hospitalisation and/or death due to COVID-19 in adults with immune-mediated inflammatory diseases: nested case-control study using linked primary-care, hospitalisation and mortality data from England. RMD open · 3 Jul 2026 PMID 42399080
Human data, design not indexed (14)
- Evaluation of Physics-Based Pose Prediction and the Role of Receptor Flexibility in a Community Antiviral Blind Challenge. Journal of chemical information and modeling · 26 Oct 2026 PMID 42929583
- Immune checkpoint inhibition enhances memory T-cell responses to CEF(T), SARS-CoV-2 spike proteins and ChAdOx1 nCoV-19. Human vaccines & immunotherapeutics · 6 Oct 2026 PMID 42836482
- Wastewater-based genomic surveillance uncovers broader SARS-CoV-2 diversity and spatial transmission dynamics in Georgia, January 2023-July 2024. Microbiology spectrum · 29 Sept 2026 PMID 42808729
- Availability and accessibility of SARS-CoV-2 vaccines among rural populations in sub-Saharan Africa: a systematic review and meta-analysis protocol. BMJ open · 24 Sept 2026 PMID 42785944
- Genomic surveillance of SARS-CoV-2 in Tunisia during the omicron era: insights from the national influenza & other respiratory viruses laboratory. Virology journal · 17 Sept 2026 PMID 42750054
- Harmonizing amplification and cleavage kinetics through crRNA scaffold mutation enables robust one-pot CRISPR-Cas12 diagnostics. Proceedings of the National Academy of Sciences of the United States of America · 9 Sept 2026 PMID 42715083
- Universal CRISPR/Cas12a-G4 DNAzyme biosensing platform for rapid detection of nucleic acid and non-nucleic acid targets. The Analyst · 1 Sept 2026 PMID 42677878
- High levels of cell-free hemoglobin and iron in cerebral thrombi of pre-Omicron COVID-19 stroke patients: novel drivers of SARS-CoV-2-induced prothrombotic state. Acta neuropathologica · 29 Aug 2026 PMID 42667425
- SARS‑CoV‑2 Associated Shifts in the Upper Respiratory Tract Mycobiome in Non-hospitalized Cases. Mycopathologia · 18 Aug 2026 PMID 42611121
- Comparative Analysis of Nucleocapsid- and Spike-Specific Isotype Humoral Immune Responses Following Natural SARS-CoV-2 Infection and Vaccination with Sinopharm, Sinovac, and AstraZeneca. Viral immunology · 7 Aug 2026 PMID 42565654
- Machine learning-based prediction of SARS-CoV-2 bioactivity: integrating IC50 regression and activity classification using multi-task neural networks. BMC bioinformatics · 6 Aug 2026 PMID 42557548
- A comparison of alternative vaccination strategies for protecting those vulnerable to illness, hospitalization, or death upon infection with SARS-CoV-2. Journal of theoretical biology · 11 Jul 2026 PMID 42435934
- Grammatical evolution-based design of nucleotic analogs for SARS-CoV-2's replication-transcription complex. Physical chemistry chemical physics : PCCP · 1 Jul 2026 PMID 42383721
- Structure-guided optimization of N-(5-((2-oxopropyl) thio)-1,3,4-thiadiazol-2-yl) propionamide frameworks as potent SARS-CoV-2 Mpro inhibitor for treating coronavirus disease. Bioorganic chemistry · 18 Jun 2026 PMID 42314596
Preclinical: animal, cell and lab studies (18)
- Exposure route, not dose, is the primary driver of infection patterns for a respiratory virus. Science advances · 7 Oct 2026 PMID 42842678
- Triple-Action Antioxidant, Antiviral, and Immunomodulatory Effects of Hypericum perforatum Against SARS-CoV-2 Using Chemical-Based and In Vitro Methods. Plant foods for human nutrition (Dordrecht, Netherlands) · 1 Oct 2026 PMID 42821038
- Co-administration of intranasal parainfluenza virus vaccines expressing antigenically distinct SARS-CoV-2 S antigens elicits broad and durable immunity in hamsters. Journal of virology · 24 Sept 2026 PMID 42782150
- Exploring the Pyrimidine Scaffold for the Development of SARS-CoV-2 Mpro Inhibitors. ACS infectious diseases · 11 Sept 2026 PMID 42725964
- Exploring the potential of Ayush-64 in mitigation of post-coronavirus disease of 2019 complications of Delta variant of severe acute respiratory syndrome coronavirus 2. Phytomedicine : international journal of phytotherapy and phytopharmacology · 10 Sept 2026 PMID 42721823
- Discovery of a new class based on 6-methoxypyrimidine as efficient low weight reversible inhibitors of SARS-CoV-2 main protease (Mpro) with antiviral activity. Bioorganic chemistry · 8 Sept 2026 PMID 42710401
- Network pharmacology, and molecular docking studies for two flavonoid compounds isolated from Dodonaea viscosa towards SARS-CoV-2 infection and loaded in lipid nanoparticles. Artificial cells, nanomedicine, and biotechnology · 7 Sept 2026 PMID 42702742
- Virus-like particle display of the SARS-CoV-2 receptor-binding domain using a modular tag/catcher system enhances immunogenicity of a DNA vaccine in mice. Vaccine · 5 Sept 2026 PMID 42700748
- Platelet-derived serotonin drives age-related lung pathology in SARS-CoV-2 infection. Science immunology · 28 Aug 2026 PMID 42664308
- Engineering antigenic breadth against SARS-CoV-2 by pairing divergent RBDs within a single mRNA immunogen. Proceedings of the National Academy of Sciences of the United States of America · 26 Aug 2026 PMID 42647127
- Development and fit-for-purpose validation of a qPCR assay for biodistribution assessment of plasmid DNA following electrode-needle device-assisted intramuscular electroporation. International journal of pharmaceutics · 19 Aug 2026 PMID 42617896
- Functional neutralizing and bactericidal antibody responses induced by dual-target immunization with SARS-CoV-2 RBD and Neisseria meningitidis antigens in mice. Vaccine · 12 Aug 2026 PMID 42585813
- The monoclonal antibody VYD2311 potently neutralizes dominant and emerging SARS-CoV-2 variants. JCI insight · 11 Aug 2026 PMID 42579364
- ACE2-PNA conjugates exploit viral endocytosis for targeted intracellular delivery and exhibit dual antiviral efficacy against SARS-CoV-2. Molecular biomedicine · 3 Aug 2026 PMID 42545604
- Broad and durable protection against SARS-CoV-2 and SARS-CoV by an intranasal chimpanzee adenovirus vaccine expressing tandem RBDs and nucleocapsid. PLoS pathogens · 24 Jul 2026 PMID 42497177
- Optimization of the antiviral spectrum of cyclophilin inhibitors targeting respiratory viruses. Antimicrobial agents and chemotherapy · 17 Jul 2026 PMID 42467054
- Discovery of broad-spectrum antiviral activity in Amaryllidaceae alkaloids. Biochemical and biophysical research communications · 8 Jul 2026 PMID 42419220
- Repurposing ALK inhibitors as influenza and corona virus antivirals targeting lymphocyte tyrosine kinase (LTK). Virus research · 9 Jun 2026 PMID 42263913
Unclassified: not yet indexed with MeSH (1)
- A Dual-Membrane Biomimetic Nanoplatform Enables Triple-Modal Therapy Against SARS-CoV-2 Through Viral Decoy, Inflammation Neutralizing, and Intracellular RNAi. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 7 Sept 2026 PMID 42702867
Written from 35 PubMed abstracts, each one listed by PMID above. Published: 2026-08-06. Last written: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.